Shares of SAGE Therapeutics Inc (NASDAQ:SAGE) have received a consensus recommendation of “Buy” from the sixteen research firms that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating and thirteen have issued a buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $199.80.
Several analysts have commented on the company. William Blair reissued a “buy” rating on shares of SAGE Therapeutics in a report on Wednesday, July 24th. JPMorgan Chase & Co. reissued a “buy” rating on shares of SAGE Therapeutics in a report on Wednesday, July 24th. Oppenheimer dropped their price objective on SAGE Therapeutics from $200.00 to $190.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. BidaskClub lowered SAGE Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, September 27th. Finally, ValuEngine lowered SAGE Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 2nd.
SAGE traded up $1.03 during trading on Friday, hitting $137.00. The company’s stock had a trading volume of 1,473 shares, compared to its average volume of 376,639. The company has a current ratio of 16.00, a quick ratio of 16.00 and a debt-to-equity ratio of 0.03. SAGE Therapeutics has a twelve month low of $79.88 and a twelve month high of $193.56. The business’s fifty day simple moving average is $156.42 and its 200 day simple moving average is $167.36. The firm has a market capitalization of $7.21 billion, a price-to-earnings ratio of -17.01 and a beta of 2.54.
In other news, Director James M. Frates sold 8,000 shares of SAGE Therapeutics stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $160.58, for a total value of $1,284,640.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 4.60% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SAGE. Dimensional Fund Advisors LP boosted its stake in SAGE Therapeutics by 40.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 109,054 shares of the biopharmaceutical company’s stock worth $10,441,000 after buying an additional 31,571 shares during the last quarter. Comerica Bank acquired a new position in SAGE Therapeutics during the first quarter worth $278,000. Great West Life Assurance Co. Can boosted its stake in SAGE Therapeutics by 10.1% during the first quarter. Great West Life Assurance Co. Can now owns 6,251 shares of the biopharmaceutical company’s stock worth $991,000 after buying an additional 574 shares during the last quarter. BlackRock Inc. boosted its stake in SAGE Therapeutics by 6.5% during the first quarter. BlackRock Inc. now owns 2,673,467 shares of the biopharmaceutical company’s stock worth $425,216,000 after buying an additional 162,976 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its stake in SAGE Therapeutics by 19.4% during the first quarter. Wells Fargo & Company MN now owns 371,305 shares of the biopharmaceutical company’s stock worth $59,057,000 after buying an additional 60,204 shares during the last quarter.
About SAGE Therapeutics
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).
Recommended Story: Understanding Market Liquidity
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.